Lycopene Promotes Osteogenesis and Reduces Adipogenesis through Regulating FoxO1/PPARγ Signaling in Ovariectomized Rats and Bone Marrow Mesenchymal Stem Cells

Nutrients. 2024 May 10;16(10):1443. doi: 10.3390/nu16101443.


Recent interest in preventing the development of osteoporosis has focused on the regulation of redox homeostasis. However, the action of lycopene (LYC), a strong natural antioxidant compound, on osteoporotic bone loss remains largely unknown. Here, we show that oral administration of LYC to OVX rats for 12 weeks reduced body weight gain, improved lipid metabolism, and preserved bone quality. In addition, LYC treatment inhibited ROS overgeneration in serum and bone marrow in OVX rats, and in BMSCs upon H2O2 stimulation, leading to inhibiting adipogenesis and promoting osteogenesis during bone remodeling. At the molecular level, LYC improved bone quality via an increase in the expressions of FoxO1 and Runx2 and a decrease in the expressions of PPARγ and C/EBPα in OVX rats and BMSCs. Collectively, these findings suggest that LYC attenuates osteoporotic bone loss through promoting osteogenesis and inhibiting adipogenesis via regulation of the FoxO1/PPARγ pathway driven by oxidative stress, presenting a novel strategy for osteoporosis management.

Keywords: BMSCs; FoxO1/PPARγ signaling; OVX rats; adipogenesis; lycopene; osteogenesis.

MeSH terms

  • Adipogenesis* / drug effects
  • Animals
  • Antioxidants / pharmacology
  • Female
  • Forkhead Box Protein O1 / metabolism
  • Lycopene* / pharmacology
  • Mesenchymal Stem Cells* / drug effects
  • Mesenchymal Stem Cells* / metabolism
  • Osteogenesis* / drug effects
  • Osteoporosis / prevention & control
  • Ovariectomy*
  • Oxidative Stress / drug effects
  • PPAR gamma* / metabolism
  • Rats
  • Rats, Sprague-Dawley*
  • Reactive Oxygen Species / metabolism
  • Signal Transduction* / drug effects


  • Lycopene
  • PPAR gamma
  • Foxo1 protein, rat
  • Forkhead Box Protein O1
  • Antioxidants
  • PPAR gamma, rat
  • Reactive Oxygen Species